New mRNA vaccine aims to shield against RSV
NCT ID NCT07694557
First seen Jul 10, 2026 · Last updated Jul 10, 2026
Summary
This early-stage trial tests an experimental mRNA vaccine called YKYY025 designed to protect against respiratory syncytial virus (RSV). Healthy adults aged 18 and older receive a single injection of either the vaccine or a placebo. Researchers monitor safety, side effects, and immune responses such as antibody and T-cell levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- YKYY025 mRNA vaccine
- What this could lead to
- If successful, this could lead to a new vaccine that protects against RSV, a common respiratory virus that can be serious for older adults.
- What could go wrong
- This is an early phase 1 trial with only 180 participants, so safety and effectiveness are not yet proven. The vaccine may cause side effects or fail to generate a strong immune response.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS (RSV) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Youcarekechuang Pharmaceutical Technology Co., Ltd.
Beijing, Beijing Municipality, 100176, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Massive RSV vaccine study uses real-world data to see if shots prevent severe illness
- New RSV vaccine aims to shield adults from severe respiratory infection
- Scientists test RSV vaccine to boost immune memory
- New study tracks RSV in pregnant women and their babies
- One shot to stop RSV: landmark trial for indigenous kids
- New RSV vaccine trial targets High-Risk adults in japan